Drug Profile
Lumretuzumab - Roche
Alternative Names: anti-HER3 monoclonal antibody - Roche; GE-HuMAb-HER3; HER3 MAb solid tumours - Roche; RG-7116; RO-5479599Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease) in France, Germany, Spain, Denmark (IV) (Roche pipeline, September 2021)
- 27 Sep 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Spain, South Korea, Denmark, Netherlands (IV) (Roche pipeline, September 2021)
- 27 Sep 2021 Discontinued - Phase-I for Solid tumours in Switzerland (IV) (Roche pipeline, September 2021)